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Objective. To develop responder definitions for
fibromyalgia (FM) clinical trials using key symptom
and function domains.
Methods. Twenty-four candidate responder defi-
nitions were developed by expert consensus and were
evaluated in 12 randomized, placebo-controlled trials of
4 medications for the treatment of FM. For each defi-
nition, the treatment effects of the medication compared
with placebo were analyzed using Cochran-Mantel-
Haenszel tests or chi-square tests. A meta-analysis of
the pooled results for the 4 medications established risk
ratios to determine the definitions that best favored
medication over placebo.
Results. Two definitions performed best in the
analyses. Both definitions included >30% reduction in
pain and >10% improvement in physical function. The
definitions differed in that one (>30% improvement in
FM [FM30] short version) included >30% improve-
ment in sleep or fatigue, and the other (FM30 long
version) required >30% improvement in 2 of the follow-
ing symptoms: sleep, fatigue, depression, anxiety, or
cognition. In the analysis of both versions, the response
rate was >15% for each medication and was signifi-
cantly greater compared with placebo. The risk ratio
favoring drug over placebo in the pooled analysis for
FM30 version 3 (short version) was 1.50 (95% confi-
dence interval [95% CI] 1.24–1.82; P < 0.0001); the risk
ratio for FM30 version 6 (long version) was 1.60 (95%
CI 1.31–1.96; P < 0.00001).
Conclusion. Among the 24 responder definitions
tested, 2 were identified as most sensitive in identifying
response to treatment. The identification of responder
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definitions for FM clinical trials that include assess-
ments of key symptom and function domains may
improve the sensitivity of clinical trials to identify
meaningful improvements, leading to improved man-
agement of FM.
Fibromyalgia (FM) is defined by the American
College of Rheumatology (ACR) as widespread pain
(duration of3 months) in combination with tenderness
at 11 or more of 18 specific tender point sites (1).
Clinically, and in clinical trials of therapy for FM,
responder indices of successful outcomes should more
broadly address the associated symptoms of fatigue and
cognitive dysfunction, sleep and mood disturbances, and
lowered functional status that influence a patient’s per-
ception of whether his or her FM has “improved” (2–4).
Currently, 3 medications are approved by the US
Food and Drug Administration for the management of
FM, including the 2 ligand pregabalin and the sero-
tonin and norepinephrine reuptake inhibitors duloxetine
and milnacipran (5–7). Recent trials have shown the
efficacy of other medications for the treatment of FM,
and continued development of new treatments is likely
(8). Evaluating the comparative efficacy of interventions
for FM is difficult, however, because no common defi-
nition of response in FM exists. At present, the inclusion
of assessment domains is inconsistent, and there is wide
variation in the use of instruments indexing those do-
mains.
An empirically derived responder definition
would facilitate the aggregation of multiple clinically
important outcomes into a single metric that could then
serve as a primary outcome in clinical trials. Clinical
decision-making could also be based on this common
metric rather than requiring clinicians to make infer-
ences about a given patient from group means in refer-
ence samples across multiple symptom domains. The
responder approach also helps identify whether im-
provement in key outcomes occurs within the same
person; such identification is a clinical necessity when
evaluating the treatment response in a condition with
the complexities of FM (9). A responder definition also
facilitates the prediction of individual responses to treat-
ments, which is an important aid to long-term treatment
planning and management of this chronic condition.
Historically, many symptoms have been thought
to be associated with FM. Because an assessment of all
symptoms in each patient is not feasible, consensus was
required to identify the key domains that needed to be
assessed to determine clinically meaningful improve-
ment. Much of the work in this area has been organized
by the Outcome Measures in Rheumatology (OMER-
ACT) FM working group (3). OMERACT is an inter-
national organization representing a partnership be-
tween academic clinicians, industry, and government
agencies sharing a common interest in promoting the
development of the best possible outcome measures for
clinical trials affecting rheumatologic conditions (10).
Delphi exercises involving both clinicians and patients
were conducted by the OMERACT FM working group
members (11,12). From both the consensus process by
clinicians and patients and the confirmation process by
analysis of clinical trials (13,14), a core domain set for
FM assessment in clinical trials and practice was estab-
lished and ratified by OMERACT. The core domains
included pain, tenderness, fatigue, patient global assess-
ment of change, multidimensional function, and sleep
disturbance. Other important domains included depres-
sion, cognitive dysfunction, stiffness, and anxiety (3).
Most clinical trials in FM have used a global
measure of improvement known as the Patient Global
Impression of Change (PGIC) scale. The PGIC scale
can be used as an index of improvement against which
each of the domain-specific measures can be mapped,
thus revealing the association between overall improve-
ment and specific symptom domains. Data derived from
FM clinical trials of pregabalin, gabapentin, duloxetine,
and milnacipran enabled the OMERACT FM working
group to evaluate the association of change within
specific symptom domains with patients’ overall impres-
sion of improvement. Results from these analyses fur-
ther supported some of the consensus-derived OMER-
ACT domains as being the most salient domains
associated with patients’ perceptions of overall improve-
ment. In the pregabalin trials, pain, fatigue, sleep, and
work and physical function were the most pronounced
independent predictors of improvement in PGIC (15).
Similarly, pain, fatigue, sleep, and physical and social
function were predictors of improvement in an FM trial
of gabapentin (16). In an assessment of data from
clinical trials of duloxetine, independent predictor vari-
ables of end point PGIC included assessments for pain,
physical function, fatigue, anxiety, social function, and
tender point thresholds (17). Among responders to
milnacipran, improvement in pain, fatigue, sleep, phys-
ical function, and cognitive symptoms were associated
with better PGIC ratings (18). Taken together, the most
consistent ranking of domains associated with PGIC
included pain, fatigue, physical function, and sleep.
The present study was designed to develop and
test candidate definitions of improvement in FM using
preexisting FM clinical trial databases, by adopting some
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of the approaches used to develop the definition of
improvement in rheumatoid arthritis (i.e., the ACR
20%, 50%, 70% improvement criteria) (19) and by
applying the data-driven consensus methods advocated
by OMERACT (10). The goal was to combine important
symptom and function domains into a responder defini-
tion, using outcome measures that were most common
across FM clinical trials and that were shown to be valid
and sensitive to change (14,20).
MATERIALS AND METHODS
Guided by the approach used in the development
of the ACR definition of improvement in RA (19), the
OMERACT FM working group identified initial drafts of
candidate responder definitions by consensus during the Eu-
ropean League Against Rheumatism 2009 Congress and at the
2009 ACR annual meeting. Six versions of responder defini-
tions were identified based on the previously reviewed core set
of clinically relevant domains (Table 1). Following the ap-
proach used by the ACR to determine criteria for improve-
ment in RA, each of the 6 draft versions contained 4 possible
definitions depending on the percent improvement (20%,
30%, 50%, and 70% [FM20, FM30, FM50, and FM70,
respectively]) in outcome measures, for a total of 24 candidate
responder definitions.
Two approaches were used for the selection of do-
mains to be included in responder definitions. First, some of
the candidate definitions included only the domains of pain,
physical function, fatigue, and sleep, which were most consis-
tently associated with PGIC in the studies reviewed above. The
second approach included additional domains to reflect the
heterogeneity of the FM population and the recognition that
some treatments may affect other domains of importance such
as depression, anxiety, and cognition. None of the candidate
definitions included an assessment of tenderness, because
tender points were not consistently evaluated in the clinical
trials of FM and, as observed in trials to date, do not appear to
be sensitive to change (21,22). Although cognitive dysfunction
was also not consistently measured in the clinical trials, this
domain was highly ranked in importance by patients, and
recent trials have begun to explore assessment of this common
symptom (23). Finally, stiffness was not included in the candi-
date definitions, because many patients report stiffness as part
of their overall pain experience.
Given that all treatments are unlikely to improve all
symptom domains, the definitions included a requirement to
meet the response criteria for pain and physical function but
allowed for flexibility in other symptom domains. In addition,
results of previous clinical trials in FM suggest that although
improvement in function is critical, in 3-month trials, the level
of improvement in function may not be the same as that in
other symptom domains. Thus, some of the definitions allowed
for a level of improvement in physical function (i.e., 10%)
that was less than the expected level of improvement in
pain (3).
When selecting outcome measures for the candidate
definitions, we were limited to those used in the clinical trials
to which we had access. Because of a lack of consensus
regarding key FM clinical domains and outcome measures
before the trials were conducted, a variety of measures were
included in the trials. To make the assessment of the candidate
responder indices as consistent as possible, we included the
Fibromyalgia Impact Questionnaire (FIQ) (24) or the Short
Form 36 (SF-36) (25), which were the only measures that were
used in all of the trials. Although the individual items on the
FIQ were not originally intended to be used in isolation to
measure specific symptoms, changes in the 10 subscale items
of the FIQ have been reported in recent studies (24). Fur-
thermore, the domains of sleep, fatigue, depression, and
anxiety were not otherwise assessed in some of the trials used
in the present analysis. For most of the definitions, the SF-36
physical function domain was selected for evaluation of phys-
ical function, which was the area of function that, among the
various dimensions of function, appeared to have the greatest
influence on patient-reported improvement in PGIC analyses
(15–18).
For the assessment of pain, we included either a
numeric rating scale (score range 0–10) or a visual analog scale
(VAS; score range 0–100) of pain severity. Cognition was
assessed in the trials of only one of the medications, using the
attention subscale of the Multiple Ability Self-Report Ques-
tionnaire, which contains items related to problems with
attention and concentration that are commonly reported by
patients with FM (26).
We recognized that the domains of sleep and fatigue
have multiple dimensions, which supports the use of multidi-
mensional measures that capture the various types of sleep and
fatigue difficulties experienced by patients with FM. There-
fore, to determine whether substituting other measures for
sleep and fatigue would yield consistent results, we tested
alternative candidate responder definitions for versions 1 and
3 that used multidimensional measures for these domains.
Possible alternative fatigue measures included the Global
Fatigue Index from the Multidimensional Assessment of Fa-
tigue (27) and the Multidimensional Fatigue Inventory (28).
Another measure for sleep was the sleep disturbance subscale
of the Medical Outcomes Study (29).
Table 1 presents the candidate responder definitions.
Each of the 6 versions was tested using 4 different levels of
improvement (total of 24 definitions). The percent improve-
ment in versions 1, 2, and 5 was the same across all domains
and ranged from 20% (FM20) to 70% (FM70). In versions
3, 4, and 6, the percent improvement in pain and associated
symptoms was the same in each definition (FM20, FM30,
FM50, and FM70), but the percent improvement in physical
function was fixed at 10%.
By consensus of the OMERACT FM working group,
the best definitions were determined by the following criteria:
1) versions in which the patient response rate was15% across
all of the drugs and was significantly greater compared with
placebo, and 2) versions in which the risk ratios of all drugs had
a lower limit of the 95% confidence interval (95% CI) of1.00
in the meta-analysis.
The candidate definitions were tested using data from
12 placebo-controlled clinical trials of 4 medications for the
treatment of FM. Based on agreement with the sponsors of
these trials, identifiable trial information was not included in
the analyses. Each definition was first evaluated using data
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from the 4 medications in order to identify the responder
definition that best differentiated treatments from placebo.
All data from the placebo-controlled FM trials were
pooled for each of the 4 medications. Only data from the
short-term placebo-controlled phase (3-month duration)
were included, and efficacious doses were combined in the
analysis. Intent-to-treat analyses were performed, imputing
missing values by using the last observation carried forward.
Patients for whom outcome measure data were missing at
baseline or thereafter and for whom the response criteria could
not be defined were excluded from the analysis; however, those
with missing outcome measure data were included if the
response could be defined from other measures. Each candi-
date response definition was assessed using a Cochran-Mantel-
Haenszel test or a chi-square test to compare the treatment
effects of the medication versus placebo while controlling for
study effect.
In addition to the individual analyses of the 4 medica-
tions, meta-analyses of the pooled results (summary statistics)
of all of the studies of the 4 medications were performed to
establish risk ratios to help identify the response definitions
that best favored the drug over placebo and to establish
discriminant validity (sensitivity to change) of the definitions.
A random-effects model was used to estimate the overall
effect.
RESULTS
Table 2 summarizes the results of the analyses of
the pooled FM clinical trials for the 4 medications. The
definitions in which the response rate was 15% and
significantly greater than placebo across all drugs were
FM20 versions 1, 3, 5, and 6 and FM30 versions 3 and 6.
Thus, versions 3 and 6 performed the best when consid-
ering both the FM20 and FM30 definitions. Because the
FM50 and FM70 candidate definitions had relatively few
responders across all of the medications, these defini-
tions were not included in the subsequent meta-analysis.
Table 3 shows the results of the meta-analysis of
the pooled data for each of the medications that estab-
lished risk ratios to help determine the definitions that
Table 1. Candidate fibromyalgia responder definitions*
Pain Physical function Associated symptoms
Version 1 20% (or 30%, 50%, 70%)
reduction (NRS or VAS)
20% (or 30%, 50%, 70%)
improvement in SF-36 physical
function
20% (or 30%, 50%, 70%)
improvement in one of the
following: fatigue (FIQ
tiredness) or sleep (FIQ
rested)
Version 2 20% (or 30%, 50%, 70%)
reduction (FIQ pain)
20% (or 30%, 50%, 70%)
improvement in FIQ physical
function
20% (or 30%, 50%, 70%)
improvement in one of the
following: fatigue (FIQ
tiredness) or sleep (FIQ
rested)
Version 3 20% (or 30%, 50%, 70%)
reduction (NRS or VAS)
10% improvement in SF-36
physical function
20% (or 30%, 50%, 70%)
improvement in one of the
following: fatigue (FIQ
tiredness) or sleep (FIQ
rested)
Version 4 20% (or 30%, 50%, 70%)
reduction (FIQ pain)
10% improvement in FIQ
physical function
20% (or 30%, 50%, 70%)
improvement in one of the
following: fatigue (FIQ
tiredness) or sleep (FIQ
rested)
Version 5 20% (or 30%, 50%, 70%)
reduction (NRS or VAS)
20% (or 30%, 50%, 70%)
improvement in SF-36 physical
function
20% (or 30%, 50%, 70%)
improvement in 2 of the
following: fatigue (FIQ
tiredness), sleep (FIQ rested),
depression (FIQ depression),
anxiety (FIQ anxiety), or
cognition (MASQ)
Version 6 20% (or 30%, 50%, 70%)
reduction (NRS or VAS)
10% improvement in SF-36
physical function
20% (or 30%, 50%, 70%)
improvement in 2 of the
following: fatigue (FIQ
tiredness), sleep (FIQ rested),
depression (FIQ depression),
anxiety (FIQ anxiety), or
cognition (MASQ)
* NRS  numeric rating scale; VAS  visual analog scale; SF-36  Short Form 36 Health Survey; FIQ  Fibromyalgia Impact Questionnaire;
MASQ  Multiple Ability Self-Report Questionnaire.
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best favored drug over placebo. The versions in which
the risk ratios of all drugs had a lower limit of the 95%
CI of 1.00 were FM20 versions 1, 3, 5, and 6 and
FM30 versions 1, 3, and 6. Table 4 summarizes the
meta-analysis results for all of the medications com-
bined. Versions 1, 3, 5, and 6 had the highest risk ratios
among the definitions, and FM30 had consistently
higher risk ratios than FM20 in each version. FM30
versions 1 and 5 had higher risk ratios with smaller
heterogeneity (I2) values compared with FM30 versions
3 and 6, respectively. However, the response rates
(Table 2) were lower for FM30 versions 1 and 5, with
some drugs having a response rate of 15%. The lower
response rates for versions 1 and 5 may be related to the
higher threshold for improvement in physical function
required in these versions. Therefore, the meta-analysis
results, combined with the response rates, suggested that
versions 3 and 6 are best for defining the response to any
Table 2. Response rates among pooled fibromyalgia trials of 4 medications, using candidate responder definitions*
Version
1 2 3 4 5 6
Placebo Drug Placebo Drug Placebo Drug Placebo Drug Placebo Drug Placebo Drug
Drug A
FM20 16.6 25.3† 20.8 28.7† 20.3 30.6‡ 23.6 31.6† 16.6 26.1‡ 19.5 32.7‡
FM30 11.7 17.1 12.7 20.0† 16.8 24.2§ 16.9 24.7† 11.1 17.5§ 15.6 25.9‡
FM50 5.5 9.9§ 6.9 11.9† 11.3 17.1§ 10.7 17.9† 5.5 12.1‡ 10.7 20.2‡
FM70 2.1 4.1 3.4 6.0 5.5 9.4§ 5.2 9.3§ 1.8 4.2 5.5 10.1§
Drug B
FM20 11.8 17.4‡ 24.4 31.0‡ 16.4 22.8‡ 27.6 33.6† 12.5 18.5‡ 17.3 25.1‡
FM30 6.5 10.9‡ 17.3 23.0‡ 12.9 18.0‡ 21.0 27.6‡ 7.2 12.0‡ 13.9 20.5‡
FM50 2.6 4.1§ 9.0 13.3† 8.1 11.6† 13.2 17.8† 2.7 4.4§ 8.3 13.2‡
FM70 0.8 1.2 3.3 6.8‡ 3.7 4.5 6.6 10.9‡ 0.9 1.2 3.7 5.4§
Drug C
FM20 15.4 31.5‡ 28.0 44.2‡ 20.8 38.4‡ 29.4 47.9‡ 15.5 31.3‡ 20.8 37.9‡
FM30 9.4 21.4‡ 23.9 35.5‡ 16.4 34.1‡ 27.1 41.0‡ 9.1 21.8‡ 15.8 34.6‡
FM50 3.8 10.3‡ 13.7 23.2‡ 9.7 25.5‡ 15.5 29.9‡ 4.7 10.1† 10.7 25.2‡
FM70 2.2 3.8 6.7 12.2† 6.6 15.5‡ 9.0 18.7‡ 2.2 4.1 6.9 16.6‡
Drug D
FM20 17.5 21.4§ 20.8 23.8 19.5 24.4§ 23.1 25.9 17.8 22.2§ 19.9 25.2§
FM30 11.2 14.6§ 15.2 17.8 14.5 18.5§ 18.9 21.0 12.0 14.8 15.1 19.3§
FM50 4.8 7.2 7.7 10.0 8.3 10.5 11.2 14.2 5.3 7.2 8.6 10.7
FM70 1.3 2.0 3.5 3.9 2.8 3.9 5.4 6.2 1.3 2.4 2.9 4.4
* Values are the percentage of responders. FM20  20% improvement in fibromyalgia symptoms.
† P  0.01 versus placebo.
‡ P  0.001 versus placebo.
§ P  0.05 versus placebo.
Table 3. Meta-analysis of pooled data from all of the medications for selected candidate responder definitions*
Version
1 2 3 4 5 6
Drug A
FM20 1.52 (1.201.93) 1.38 (1.121.70) 1.51 (1.221.85) 1.34 (1.111.62) 1.57 (1.241.98) 1.68 (1.362.06)
FM30 1.46 (1.091.95) 1.57 (1.202.07) 1.44 (1.131.82) 1.46 (1.151.84) 1.58 (1.172.13) 1.66 (1.312.12)
Drug B
FM20 1.47 (1.201.81) 1.27 (1.111.45) 1.39 (1.171.65) 1.22 (1.071.38) 1.48 (1.221.80) 1.45 (1.231.71)
FM30 1.69 (1.282.23) 1.33 (1.131.57) 1.40 (1.15–1.70) 1.31 (1.131.52) 1.67 (1.282.17) 1.48 (1.231.78)
Drug C
FM20 2.04 (1.542.71) 1.58 (1.311.91) 1.85 (1.462.34) 1.63 (1.361.95) 2.03 (1.532.69) 1.82 (1.442.31)
FM30 2.26 (1.563.28) 1.49 (1.201.84) 2.09 (1.592.73) 1.51 (1.241.84) 2.38 (1.643.47) 2.19 (1.662.89)
Drug D
FM20 1.23 (1.001.51) 1.14 (0.951.38) 1.25 (1.031.51) 1.12 (0.941.34) 1.25 (1.021.52) 1.27 (1.051.53)
FM30 1.30 (1.001.70) 1.17 (0.931.47) 1.28 (1.021.60) 1.11 (0.911.36) 1.23 (0.961.59) 1.28 (1.021.60)
* Values are the risk ratio (95% confidence interval). FM20  20% improvement in fibromyalgia symptoms.
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of the drugs compared with placebo. For both versions 3
and 6, FM30 definitions had greater risk ratios com-
pared with the FM20 definitions. Figure 1 presents the
forest plots for FM30 versions 3 and 6.
We also analyzed FM30 version 3 using alterna-
tive sleep and fatigue measures. For 2 of the drugs,
alternative multidimensional measures for both fatigue
and sleep were used across most of the trials. In the
meta-analyses of these trials that included alternative
measures, the total risk ratio for the alternative FM30
was 1.37 (95% CI 1.15–1.64, P  0.0004).
DISCUSSION
The development of candidate responder defini-
tions for FM trials is the result of several years of
preliminary work that included multiple steps. We re-
viewed previous criteria for a response to treatment in
FM involving multiple symptom domains. Several early
definitions have limited utility now, because they in-
cluded various assessments of tender points, which have
Figure 1. Forest plots of A, FM30 (30% improvement in fibromyalgia symptoms) version 3 and B, FM30 version 6. Risk ratios and 95%
confidence intervals (95% CIs) are presented, along with the results for heterogeneity. The overall effect was obtained using a random-effects model
with Mantel-Haenszel (M-H) tests. Both versions showed that all drugs were statistically significantly superior compared with placebo.
Table 4. Meta-analysis of pooled data for all of the medications
combined for selected candidate responder definitions*
RR (95% CI) Heterogeneity, % P†
Version 1
FM20 1.52 (1.251.83) 64 0.0001
FM30 1.60 (1.301.98) 51 0.0001
Version 2
FM20 1.33 (1.171.51) 51 0.0001
FM30 1.37 (1.221.53) 13 0.00001
Version 3
FM20 1.47 (1.261.70) 56 0.00001
FM30 1.50 (1.241.82) 63 0.0001
Version 4
FM20 1.31 (1.131.52) 69 0.0005
FM30 1.33 (1.181.52) 43 0.00001
Version 5
FM20 1.53 (1.271.83) 62 0.00001
FM30 1.63 (1.282.08) 64 0.0001
Version 6
FM20 1.52 (1.311.77) 57 0.00001
FM30 1.60 (1.311.96) 68 0.00001
* RR  relative risk; 95% CI  95% confidence interval; FM20 
20% improvement in fibromyalgia symptoms.
† Obtained from a random-effects model using the Cochran-Mantel-
Haenszel test.
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not been consistently included as outcome measures in
recent pivotal FM trials (30–33). In addition, some of
the definitions did not include a change in pain, which is
a cardinal feature of FM (32), or many of the other key
symptom or function domains now recognized as clini-
cally relevant (33).
More recently, composite responder definitions
were used in FM trials of milnacipran and sodium
oxybate. In the milnacipran trials, the composite re-
sponder definition for the treatment of FM consisted of
3 components: 1) 30% improvement from baseline in
pain, 2) a rating of “very much improved” (score 1) or
“much improved” (score  2) on the PGIC scale, and
3) 6-point improvement from baseline in physical
function (SF-36 Physical Component Summary [PCS]
score) (25). For the treatment of pain associated with
FM, a 2-measure composite response definition in-
cluded only the pain and PGIC components described
above (34). The response definitions used in the mil-
nacipran trials addressed some of the limitations of the
previously proposed response criteria by including an
assessment of function, but they did not include many of
the other clinically relevant symptom domains identified
by the OMERACT FM working group (3). In addition,
the PCS score is a summary measure of multiple scales
of the SF-36 designed to assess physical health, including
body pain, and does not measure physical function
alone. In the sodium oxybate trials, the composite
responder definition was as follows: 1) 30% improve-
ment in the VAS score for pain, 2) 30% improvement
in the FIQ total score, and 3) a rating of “much better”
or “very much better” on the PGIC scale (35). As in the
case for the milnacipran studies, the responder defini-
tion used in the sodium oxybate studies did not contain
many of the other key symptom domains as defined by
the OMERACT FM working group. Although the
FIQ total score reflects the impact of multiple symp-
toms (including pain) and function domains, it does not
provide information about an individual’s response to
specific domains (24).
To address the limitations of previous FM re-
sponder definitions, we adopted some of the approaches
used to develop the ACR definition of improvement in
RA (19) and applied the data-driven consensus methods
advocated by OMERACT (10). Because we recognized
that FM is associated with multiple symptom and func-
tion domains, we identified key domains of FM through
patient focus groups and patient and clinician Delphi
exercises (11,12). After a review of the results of these
patient and clinician studies and a confirmation process
by analysis of clinical trials (13,14), a list of core domains
was selected by consensus as part of an OMERACT
module on FM (3). We then conducted analyses of
existing FM clinical trial databases to determine which
of the domains drove patients’ perception of improve-
ment (15–18). We evaluated the performance character-
istics of outcome measures for the core domains to
assess their face, construct, content, and criterion valid-
ity as well as sensitivity to change (14,20). Finally, in the
present study, we combined core symptom and function
domains to develop candidate responder definitions,
using outcome measures that were most commonly used
across FM clinical trials and were found to be valid and
sensitive to change. We tested candidate responder
definitions using existing FM clinical trial databases.
The candidate definitions included a combina-
tion of key symptom and function domains. We observed
that the responder definitions that best favored drug
over placebo included improvement in pain and physical
function as well as improvement in either sleep or
fatigue (FM30 version 3 [short version]). Along with
pain, sleep disturbance and fatigue have been consis-
tently ranked by patients and clinicians as being among
the most common and troublesome symptoms of FM
(3). The other responder definition that performed well
in the analysis (FM30 version 6 [long version]) included
additional symptom domains of depression, anxiety, and
cognitive dysfunction to reflect the heterogeneity of the
FM population and the recognition that some treat-
ments may affect these other domains of importance. A
responder definition that includes improvement in spe-
cific key symptom domains in addition to pain evaluates
the broader impact of FM on patients and addresses the
limitations of other composite responder definitions for
FM trials that focused only on the symptom of pain.
The best responder definitions (FM30 versions 3
[short version] and 6 [long version]) included at least
30% improvement in the symptom domains. This is
consistent with other studies that showed that at least
30% improvement in pain represents a clinically impor-
tant improvement in chronic pain disorders (36,37),
including FM (38). There are few published data on
clinically important changes in other FM symptom do-
mains such as sleep and fatigue, and to our knowledge,
there are no published data on clinically important
changes in multiple symptom domains that are part of a
composite responder definition. However, in support of
requiring the same level of improvement in other symp-
tom domains (e.g., 30%) as is required for the pain
domain, a recent pooled analysis of duloxetine FM
clinical trials showed that patients who reported feeling
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much or very much better had similar levels of improve-
ment in pain, sleep, and fatigue (39).
For the assessment of symptoms of sleep and
fatigue, we included definitions that used 10 FIQ single
items for morning tiredness (a measure of refreshing
sleep) and fatigue. We also tested multidimensional
measures for sleep and fatigue and observed that the
results were consistent with findings that used single FIQ
items. Future studies should evaluate the responder
definitions using new outcome measures such as those
being developed within the National Institutes of Health
Patient-Reported Outcomes Measurement Information
System (PROMIS) initiative, a collaborative effort to
develop patient-reported outcomes for a wide variety of
chronic diseases and conditions (40).
FM affects multiple dimensions of function, but
analyses of previous clinical FM trials suggested that
physical function had the greatest influence on patient-
reported improvement (15–18). Therefore, when func-
tion was assessed by the responder definitions, only an
assessment of physical function was used. Both FM30
versions 3 and 6 used the SF-36 physical function scale to
assess function. Versions that used the alternative mea-
sure of physical function, the FIQ function component,
did not perform as well as the versions using the SF-36.
This may be related to the observation that the FIQ
function component is oriented toward individuals with
severe FM and high levels of disability, resulting in a
potential floor effect for those with milder disease (41).
Recently, a revised FIQ in which the function questions
were modified was shown to be better correlated with
the SF-36 physical function scale and may be considered
for inclusion as an outcome measure in future studies of
the responder definitions, along with other measures of
function developed through PROMIS (42).
Several limitations of this study should be consid-
ered. First, as noted above, the analyses were based on
completed FM clinical trials that were conducted before
consensus was reached on key symptom and function
domains in FM. Therefore, we were limited in the choice
of outcome measures when developing the responder
definitions, and some of the important domains (e.g.,
cognition) were not consistently evaluated across the
trials. In addition the trials used variable measures to
assess symptoms such as sleep disturbance and fatigue.
However, our analyses suggest that different measures
of a clinical domain can be substituted in the definitions,
as is done in the ACR responder criteria for RA.
Second, all of the trials used the FIQ and the
SF-36, which allowed for some consistency in evaluating
the domains. As noted, the SF-36 appeared to be a
better assessment of physical function compared with
the FIQ; however, the individual FIQ items for sleep
and fatigue performed similarly to more multidimen-
sional scales, suggesting that simple numeric scales may
be sufficient for the evaluation of some domains.
Third, there was little difference between several
of the definitions in terms of their ability to detect a
response to medication. Therefore, the definitions cho-
sen should be regarded as a useful first step in the
development of response criteria based on this method.
Fourth, although we obtained consensus from
OMERACT about the appropriateness of the proposed
responder definitions (4), we have not yet obtained
patient feedback on the responder definitions, which is
planned for the future.
Finally, in addition to responder definitions,
there is a need for an assessment of worsening and flare
as well as a measure for monitoring disease activity over
time, as has been recommended by OMERACT (4).
These additional studies will be described in a future
report.
The FM responder definitions that were identi-
fied as the most sensitive in identifying response to
treatment in analyses of existing clinical trials of 4
medications in FM included FM30 version 3 (short
version) and version 6 (long version). These definitions
share common features in that they require 30%
reduction in pain and 10% improvement in physical
function. FM30 version 3 also requires 30% improve-
ment in sleep or fatigue, while FM30 version 6 requires
30% improvement in 2 of the following symptoms:
sleep, fatigue, depression, anxiety, or cognition. These
responder definitions can be used to improve the assess-
ment of a patient’s response to treatment. Future studies
should explore the use of these responder definitions in
FM clinical trials.
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